An experimental migraine pill from Biohaven Pharmaceuticals (BHVN) hit its primary endpoints of beating placebo in pain relief and prevention of symptoms including light sensitivity and nausea in two Phase 3 clinical trials, the company announced Monday.
With the study results, Biohaven said it will submit a marketing application for the migraine drug, called rimegepant, with the Food and Drug Administration next year.
I’m seeking information on clinical study for mental chemical I. Please call415-336-0855.